Technology Reference / Liquids & Semisolids / Nano-Emulsification & Liposomal Suspension
Liquids & Semisolids

Nano-Emulsification & Liposomal Suspension

Driving droplets or lipid vesicles down to the nanometre scale with high-energy homogenization — to carry a poorly soluble active in a clear, water-based product and improve how it’s absorbed.

Nano-emulsification is one of the liquid and semisolid unit operations — the family that mixes, emulsifies, and suspends actives into pourable, spreadable products.See the other liquids & semisolids technologies The poorly soluble active often starts as an extract or oil isolated upstream in the extraction and separation family before it’s emulsified.See the extraction & separation technologies The nano-emulsion or liposomal suspension can be carried forward and encapsulated into a softgel or microcapsule dose form downstream.See the encapsulation & solid-dose technologies
What it is

Make the droplet tiny enough to change how it behaves.

Nano-emulsification reduces oil-in-water droplets — or builds lipid vesicles, liposomes — to the nanometre scale using high-energy homogenization, to improve the solubility, absorption, or delivery of an active. The droplets or vesicles are so small and uniform that they stay suspended, look clear or translucent, and can carry a poorly soluble active in a water-based product where it otherwise couldn’t go.

Size is what changes the behavior: below a certain scale an emulsion stops looking milky, stops creaming, and starts behaving more like a solution — and a liposome can wrap the active in a lipid shell that targets how it’s delivered.

The levers are the surfactant/lipid system, homogenization pressure and passes, temperature, and the resulting size distribution. The system chemistry decides whether the nanoscale droplets stay stable; the homogenizer decides whether you reach the size at all, and how reproducibly.

A coarse pre-emulsion is formed, then driven through a high-pressure homogenizer or microfluidizer — often several passes — to push size into the nanoscale; for liposomes, lipids self-assemble into vesicles around the active. Particle size is verified and the bulk stabilized.

Process flow
1

Oil phase (with the lipophilic active or lipids) and aqueous phase with surfactant prepared

2

Coarse pre-emulsion formed

3

Pre-emulsion passed through a high-pressure homogenizer or microfluidizer (often multiple passes) to reach the nanoscale

4

For liposomes: lipids self-assemble into vesicles encapsulating the active

5

Particle-size distribution verified; bulk stabilized

A nano-emulsion or liposomal suspension at a controlled particle size

The leversThe surfactant/lipid system, homogenization pressure and passes, temperature, and the resulting size distribution.
Why it matters

The whole benefit rides on reaching — and holding — the size.

Better absorption, a clear product, a delivery claim — all of it depends on actually reaching the nanoscale and on the active staying encapsulated. Particle size is the critical attribute here, full stop. If it drifts large, or the system destabilizes through Ostwald ripening or aggregation, both the bioavailability claim and the appearance fail at once.

And because the appeal is often an enhanced-absorption claim, the product invites substantiation scrutiny that a plain emulsion doesn’t. The discipline is per-batch particle-size data against a defined spec, demonstrated physical stability over shelf life, measured encapsulation efficiency for liposomes, controlled and recorded homogenization pressure and passes, real substantiation behind any absorption claim, and specified lipid/surfactant grade with oxidation control.

21 CFR 211 · drugWhen the product is a drug, this is the cGMP rule — it governs how you make the emulsion, control particle size, and prove each batch matches the label.
21 CFR 111 · supplementIf the product is a dietary supplement, this sets the cGMP requirements for the identity, purity, and composition of the finished suspension.
MoCRA · cosmeticsFor a cosmetic emulsion, MoCRA requires facility registration, product listing, and safety substantiation for the formulation.
FTC · claim substantiationAny absorption or bioavailability claim you make for the smaller droplet has to be backed by competent and reliable evidence before it runs.

The governing rule follows the product class; a particle-size spec, physical-stability data, and substantiation for any absorption/bioavailability claim anchor the rest.

How it compares

Why a maker goes nano — and what they trade.

Nano and liposomal delivery buy absorption and clarity. Knowing what it was chosen over tells you what the active needed.

vs.

Conventional (macro) emulsion

A macro-emulsion is simpler and needs no high-energy equipment.

The tradeNano-emulsions resist creaming, look clear, and can boost bioavailability — but need high-energy equipment and careful surfactant selection.
vs.

Microencapsulation

Microencapsulation protects dry particles for a solid product.

The tradeLiposomes and nano-emulsions deliver in a liquid and target absorption instead.
vs.

Simple solubilization

Solubilizing with co-solvents is the low-tech route to a clear liquid.

The tradeWhere an active won’t dissolve, nano/liposomal carries it without a heavy co-solvent load.
Where it tends to go wrong

The gaps a reviewer looks for on a nano-emulsion.

None of these are exotic. They’re the quiet places a nano or liposomal product drifts away from its own claim — recognizable the moment you’ve run one.

Particle-size distribution isn’t measured per batch, or has no spec — so the nano claim is unverified.

Physical stability isn’t demonstrated — ripening, aggregation, and size growth over shelf life left unproven.

Encapsulation efficiency for liposomes isn’t measured.

Homogenization pressure and passes run uncontrolled, so size varies run to run.

Enhanced-absorption or bioavailability claims lack substantiation.

Surfactant/lipid grade and oxidation aren’t specified or tracked.

If this is your operation

Six things to check against your own records.

Not an audit — a read you can run yourself before anyone else does. Pull one recent batch and walk it.

01

Ask for per-batch particle-size data against a defined spec.

02

Check physical-stability data (size growth, aggregation) over shelf life.

03

For liposomes, review encapsulation efficiency.

04

Confirm homogenization pressure and pass count are controlled and recorded.

05

Look at the substantiation behind any absorption or bioavailability claim.

06

Review lipid and surfactant grade and oxidation controls.

Applications

The same operation, across very different actives.

The active and carrier change — the discipline never does: reach the size, prove it holds, substantiate the claim.

Supplement

Enhanced-absorption actives

Carrying poorly soluble nutraceuticals — curcumin, CoQ10, cannabinoids — in nano or liposomal form, where the absorption claim has to be substantiated and the size proven.

Pharma

Liposomal & nano drug delivery

Encapsulating drugs in liposomes or nano-emulsions to target delivery and raise bioavailability, with size and encapsulation as critical quality attributes.

Cosmetic

Clear serums & delivery systems

Building clear, fast-absorbing serums and liposomal delivery for skincare actives under MoCRA, where clarity and stability are the appeal.

Food & beverage

Clear functional beverages

Dispersing oil-soluble flavors and actives into clear beverages without clouding, where nanoscale droplets stay invisibly suspended.